Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort

@inproceedings{Qiu2015SafetyPO,
  title={Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort},
  author={Y. P. Qiu and Ren Mao and Sheng-hong Zhang and Man-ying Li and Jing Song Guo and Bai‐li Chen and Yao He and Zhi‐rong Zeng and Min‐hu Chen and Luisa Guidi},
  booktitle={Medicine},
  year={2015}
}
AbstractThiopurines have been associated with both clinical improvement and mucosal healing in treating Crohn disease (CD). Unfortunately, the high rate of adverse events (AEs) leading to drug withdrawal represents a major limitation in the use of these drugs.To evaluate the safety of thiopurines in patients with CD. To identify predictive factors associated with the development of thiopurine-induced AEs and withdrawal.This longitudinal cohort study examined patients from a university-based IBD… CONTINUE READING
2
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Crohn Disease: Epidemiology, Diagnosis, and Management

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the patients with Crohn’s disease

  • JI Warman, BI Korelitz, MR Fleisher
  • Eur J Gastroenterol Hepatol. 2004;16:207–212
  • 2015

The consensus statement on diagnoses and treatment of inflammatory bowel disease (2012 Guangzhou)

  • Hu P-J, Qian J-M, Wu K-c
  • Chin J Dig
  • 2013